RE:Resistance to ADCs in the treatment of solid tumors May 15, 2024 - A recent ADC+ ICI combination study in TNBC presented at ESMO 2024 showed that treatment with the combination of atezolizumab (Tecentriq) plus sacituzumab govitecan-hziy (Trodelvy) led to responses in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who had a PD-L1 expression of at least 1% on immune cells (PD-L1 positive), according to data from an 18-week interim analysis of the phase 1b/2 MORPHEUS-pan BC trial (NCT03424005) "
https://www.onclive.com/view/frontline-atezolizumab-plus-sacituzumab-govitecan-elicits-responses-in-pd-l1-advanced-tnbc
[ ONCY's pelareorep has demonstrated that it's responsive to PD-L1 negative cancers. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response, that pelareorep is able to achieve through a resulting expansion of both pre-existing and new T cell clones (TiLs) in the tumor microenvironment (TME).
Results of pelareoreps's effectiveness in generating a CD8+ TiLs complex response will be presented during this week ASCO 2024 Trials in Progress poster session.
As discussed, earlier, pelareorep's ability to stimulate the immune system with consequential TiLs expansion precludes T cell exhaustion and complements both ADC and ICI therapies, with either agent, or in combination with both.]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154949/